Intensity Therapeutics, Inc. , a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors.
Intensity Therapeutics stock last closed at $1.94, up 4.86% from the previous day, and has decreased 50.26% in one year. It has overperformed other stocks in the Biotechnology industry by 0.27 percentage points. Intensity Therapeutics stock is currently +29.33% from its 52-week low of $1.50, and -63.22% from its 52-week high of $5.28.
At the moment, there are 15.18M INTS shares outstanding. The market value of INTS is $29.45M. In the last 24 hours, 7390 INTS shares were traded.
How to Buy Intensity Therapeutics Stock
Wondering how to invest in Intensity Therapeutics stock? Here's how.
Figure out where to buy Intensity Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you decide where to buy Intensity Therapeutics stock.
Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Fund your brokerage account: Choose your method of payment and add your info.
Evaluate Intensity Therapeutics stock: The Intensity Therapeutics ticker symbol is INTS. Is Intensity Therapeutics stock a good investment? Should you buy shares of INTS? How do INTS's underlying business fundamentals look? Do top analysts think Intensity Therapeutics is a good buy? Why has INTS's stock price moved recently? (Hint: Our stock research website can help you understand if INTS is a good stock to buy).
Make your INTS buy order: Decide if you will purchase INTS shares at the current market price or use a limit order to purchase INTS stock at a particular price.
Get the latest scoop on your investment in INTS: Create a watchlist to track your new investment in Intensity Therapeutics stock.
Step 1: Figure out where to buy Intensity Therapeutics stock
You will need a brokerage account to access the NASDAQ market and buy INTS stock.
A brokerage account allows you to buy and sell a variety of investments, including stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
In our opinion, eToro is the best brokerage. eToro gives you:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to world financial markets: From Tech to Real Estate, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's leading exchanges.
Social investing: eToro has a community with more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Open a brokerage account
Now that you've picked the right brokerage, the next step is to fill out some personal information so you can buy INTS stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Intensity Therapeutics stock
After you have figured out the best place to buy Intensity Therapeutics stock, it's very important to evaluate their stock before you buy, so you truly understand the risk as well as the upside.
Intensity Therapeutics shares quick numbers
INTS Price
$1.94
1w %
3.74%
1y %
-50.26%
5y %
N/A
P/E
-1.66x
P/B
10.09x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$16.27M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$29.45M
Next Earnings
N/A
Next Dividend
N/A
Intensity Therapeutics Due Diligence Score
WallStreetZen was designed to help everyday investors perform more accurate fundamental analysis quickly.
Over the past 12 months, executives and large shareholders at INTS have bought more shares than they have sold.
John M. Wesolowski, Principal Accounting Officer of INTS, was the latest INTS insider to buy. They bought $4,000.00 worth of INTS shares on Jun 5, 2024.
No, Intensity Therapeutics doesn't provide an income stream by paying out dividends.
What do other investors have to say about INTS?
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your INTS buy order
You have two primary order types:
Market order: A market order is an order to buy or sell a security at the best possible price. Market orders are generally fine for most investors.
Limit order: A limit order is an order to buy or sell a security at a specific price (or better). If you want to be sure you're buying or selling at an exact dollar amount, use a limit order.
Hit the Open Trade button and eToro will execute the order.
If you require additional help investing in stocks on eToro, click the helpful video below:
How much does it cost to buy one Intensity Therapeutics share?
As of Apr 21, 2025, it costs $1.94 to buy one share of Intensity Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.97, you can buy 0.5 shares of INTS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.